VSV-SARS-CoV-2 vaccine (Washington University School of Medicine)

N/A

Report date: 2025/01/26 17:34:01

Base Information

Drug NameVSV-SARS-CoV-2 vaccine (Washington University School of Medicine)
Drug Alias Namevesicular stomatitis virus vector based vaccine targeting spike glycoprotein (Washington University School of Medicine)
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionCoronavirus spike glycoprotein modulators
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Pneumonia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesWashington University School Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesWashington University School Of Medicine
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Pneumonia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A